Introduction
Exposure of cells to DNA-damaging agents provokes the induction of mutations, chromosomal aberrations and malignant transformation. These detrimental effects may be abrogated by cell killing, exerted notably by programmed cell death (apoptosis) eliminating genetically altered cells. Although the molecular pathways evoked by death receptor activation have been elucidated in great detail (Peter and Krammer, 2003) , the mechanism of DNA-damage-triggered apoptosis is only poorly understood. A prerequisite for this understanding would be to identify a particular type of DNA lesion that triggers apoptosis. Various anticancer drugs with methylating properties (such as temozolomide, procarbazine and dacarbazine) target DNA, inducing about a dozen DNA methylation products (Beranek, 1990) . qOne of them, O 6 -methylguanine (O 6 MeG), comprising o8% of DNA alkylations, has been identified as the major lesion leading to apoptosis. This has been unequivocally proven by the utilization of cell lines that are defective in the repair of O 6 MeG due to the loss or inactivation of the repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) (for review see Margison and Santibanez-Koref, 2002) . Cells expressing MGMT (Mex þ ) are highly resistant to the killing effect of methylating agents, compared to MGMT-deficient (Mex À ) cells, and display a lower frequency of apoptosis (Kaina et al., 1997; Tominaga et al., 1997; Meikrantz et al., 1998) . Also, they are protected against the mutagenic, genotoxic and carcinogenic effect of O 6 -alkylating agents, establishing that O 6 MeG is not only an apoptotic but also a major mutagenic, genotoxic and tumor-initiating lesion (Kaina et al., 1993; Becker et al., 1996; Margison and Santibanez-Koref, 2002) .
The identification of O
6
MeG as an apoptotic DNA lesion has made it possible to elucidate the chain of events leading to apoptosis in great detail. The current model, supported by a broad range of evidence, suggests that O 6 MeG pairs with thymine, forming a mismatch that is subject to mismatch repair (MMR) (Karran and Stephenson, 1990; Kat et al., 1993; Duckett et al., 1996) . Owing to repetitive, faulty MMR cycles provoked by the mispairing properties of O 6 MeG, secondary DNA lesions are formed, which either directly or upon interference with DNA replication trigger chromosomal damage and cell death, which is executed mainly by apoptosis (Galloway et al., 1995; Kaina et al., 1997; Hickman and Samson, 1999) . Cells defective in MMR are highly resistant to O 6 MeG-generating agents such as the model alkylating drug N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) and similar acting anticancer drugs (Kat et al., 1993; Dosch et al., 1998; Marra et al., 2001) . Therefore, both the efficiency of prereplicative repair by MGMT as well as postreplicative MMR determine the level of O 6 MeG-triggered genotoxicity and cell death. Work with rodent fibroblasts showed that a hallmark of O 6 MeG-triggered apoptosis is the decline of Bcl-2. The Fas/CD95/Apo-1 pathway was not significantly activated, indicating that O 6 MeG triggers mainly the mitochondrial damage pathway in fibroblasts involving cytochrome c release from mitochondria and caspase-9/-3 activation (Ochs and Kaina, 2000) . This was independent of p53 as the cells were mutated in the gene coding for this protein (Dunkern et al., 2001b) .
The model proposed previously and outlined above implicates DNA replication as an essential element for eliciting the apoptotic response triggered by O 6 MeG. Also, DNA double-strand breaks (DSBs) generated during MMR in conjunction with DNA replication were suggested to be critically involved as downstream lesions (Ochs and Kaina, 2000) . Alternatively, one might assume that the MMR complex itself provides the signal downstream to the apoptotic machinery. Here, we examined the role of DNA replication as well as DSBs in apoptosis in human cells. To this end, we compared human peripheral lymphocytes that were nonproliferating with lymphocytes stimulated to divide. Using this approach, we wished, additionally, to determine whether hematopoietic cells behave in the same manner as fibroblasts with respect to the apoptotic pathways triggered by O 6 MeG. We show that the O 6 MeGgenerating agents MNNG and temozolomide provoke apoptosis exclusively in proliferating, MGMT-depleted lymphocytes following treatment with low doses of the agents. With high-dose exposure, however, apoptosis was independent of MGMT depletion and occurred both in resting and dividing cells, suggesting lesions other than O 6 MeG to be involved. O MeG-triggered apoptosis in stimulated lymphocytes was a late response preceded by the induction of DSBs and p53 upregulation. Furthermore, the death receptor Fas/CD95/APO-1 was enhanced in expression, whereas Bcl-2 and Bax remained unaffected. Upon inhibition of the Fas receptor, apoptosis was drastically reduced. This indicates that in lymphocytes, O 6 MeG triggers apoptosis by activating the receptor-driven pathway rather than targeting the mitochondria. Obviously, depending on the cellular background, O 6 MeG is able to activate either the Fas or the Bcl-2-driven pathway, with DNA replication to be essentially involved.
Results

Apoptosis upon genotoxic treatment in nonproliferating versus proliferating lymphocytes
To study the effect of cell proliferation on apoptosis, human peripheral lymphocytes, which were nonproliferating, were stimulated to divide. This occurred efficiently by treatment with anti-CD3 and anti-CD28, which activate the corresponding receptors thus pushing cells into the cell cycle (see Figure 1a, (Moschel et al., 1992) prior to MNNG exposure. Apoptosis was quantified by determining subG1 fraction (for an example, see Figure 1c ,d). The slight subG1 peak that is seen in Figure 1c is independent of MNNG treatment as some nonspecific apoptosis does occur after 96 h in nonproliferating lymphocytes, as seen in Figure 2c . In Figure 2a , MNNG did not induce apoptosis in resting lymphocytes at dose levels o10 mM. With higher doses, slight apoptotic effects were observed both in MGMT-depleted and nondepleted cells. These results sharply contrast with proliferating lymphocytes (Figure 2b) MeG. Interestingly, at high MNNG concentrations (X15 mM) that are highly genotoxic both in MGMTproficient and -deficient cells (Kaina et al., 1991) , slight but significant induction of apoptosis was also seen in proliferating cells not pretreated with O 6 BG ( Figure 2b ) and in resting lymphocytes, irrespective of whether they were depleted of MGMT or not (Figure 2a) . Obviously, at high doses of MNNG (above 10 mM) apoptosis in resting cells is not induced by O 6 MeG but by other lesions, which are presumably N-alkylations.
Time-course analysis (Figure 2c, d) showed that apoptosis in proliferating lymphocytes is a late response, occurring beyond 24 h after MNNG treatment. Again, in nonproliferating lymphocytes apoptosis was induced only at a very low level and O 6 BG did not exert an enhancing effect (Figure 2c ), whereas in proliferating lymphocytes apoptosis increased with time in O 6 BGpretreated cells (Figure 2d ). Similar results were obtained with the anticancer drug temozolomide that acts similar to MNNG. As shown in Figure 3 , within a low-dose range, temozolomide provoked apoptosis selectively in proliferating and MGMT-depleted lymphocytes. However, with a high dose (1 mM) apoptosis was also observed in nonproliferating cells as well as in proliferating cells not pretreated with O 6 BG. This supports the previous conclusion that a high dose of a methylating agent induces lesions other than O 6 MeG It was interesting to study, for comparison, the effect of ionizing radiation in the same cell system. Treatment with 5 Gy of g-radiation induced apoptosis with similar efficiency in stimulated and resting lymphocytes (Figure 4) , showing simultaneously that nonreplicating lymphocytes are able to undergo apoptosis and that lesions induced by ionizing radiation are able to trigger apoptosis in lymphocytes in a replication-independent way.
DNA double-strand break formation upon MNNG treatment
Previously, we proposed, on the basis of data obtained with CHO cells, that O 6 MeG is converted via DNA replication into DSBs, which represent the ultimate trigger of methylation-induced apoptosis (Ochs and Kaina, 2000) . Therefore, we studied DSB formation in lymphocytes after treatment with low doses of MNNG. As shown in Figure 5a , proliferating lymphocytes responded to MNNG treatment (10 mM) with a high yield of DSBs, whereas in resting cells DSB formation was much lower. DSBs in proliferating lymphocytes peaked at 24 h after MNNG exposure, which clearly preceded the onset of apoptosis (compare with Figure 2d ). This supports the model that O
6
MeG is converted via DNA replication into DSBs, which in turn trigger apoptosis. Interestingly, at high doses of MNNG (>25 mM), DSBs, as determined by the neutral comet assay, were induced at equal frequency in proliferating and nonproliferating lymphocytes. This DSB formation seems to occur directly because it was detectable already 3 h after MNNG treatment ( Figure 5b ). This was confirmed by determining the amount of H2AX phosphorylation, which is a sensitive indicator of DSB formation (Rogakou et al., 1998 ). The H2AX-P level was enhanced 6 h after MNNG treatment both in resting and proliferating cells (Figure 5c ). The replication-independent formation of DSBs at high dose levels (>15 mM) is in agreement with the observed replication independence of apoptosis within this dose range.
p53 expression upon MNNG treatment
Next we wished to know whether O 6 MeG-triggered apoptosis in proliferating lymphocytes is dependent upon p53. As shown in Figure 6a Fas, Bcl-2 and Bax in O 6 MeG-triggered apoptosis in lymphocytes p53 has been implicated in the regulation of the Fas receptor. Indeed, Fas expression increased in proliferating lymphocytes with nearly the same time-course as p53 (Figure 7) . In resting lymphocytes, Fas was not detectably expressed both at the basal level and within the 72 h period after MNNG exposure. Bcl-2 and Bax levels remained unchanged in proliferating and resting cells (Figure 7) . Overall, the data show that in proliferating, but not resting, lymphocytes the specific DNA damage O 6 MeG triggers not the mitochondrial but the Fas-mediated apoptotic pathway.
Inhibition of apoptosis with Anti-Fas neutralizing antibody
To verify the role of Fas in MNNG-induced apoptosis, we neutralized the Fas receptor using an anti-Fas neutralizing antibody. As shown in Figure 8 , blocking the Fas receptor decreased apoptosis in proliferating lymphocytes by 61%. This clearly demonstrates the importance of the Fas-mediated death receptor pathway in apoptosis induced by MNNG.
Discussion
Whereas the molecular events in apoptosis triggered by activation of cell-surface receptors are well described, only little is known about how particular types of DNA damage activate intracellular signaling that finally give rise to cell death. Previous work with isogenic cell lines differing in MGMT and mismatch repair activity has shown that O MeG in rodent fibroblasts is apoptosis. Necrosis was only marginally induced, indicating O 6 MeG to be a powerful proapoptotic DNA lesion (Kaina et al., 1997; Tominaga et al., 1997; Meikrantz et al., 1998; Hickman and Samson, 1999) . The mechanism involves DNA mismatch repair since MMR-defective cells are refractory to O 6 MeGinduced apoptosis (Hickman and Samson, 1999; Ochs and Kaina, 2000) . Based on this, two alternative models have been proposed: the MMR proteins MSH2 and MSH6 that form the MutSa complex bind to O 6 MeG/C and O 6 MeG/T lesions (Duckett et al., 1996) , thus acting as a sensor of DNA damage delivering a downstream signal activating the apoptotic cascade (Fishel, 1999) . Alternatively, it has been suggested that MMR, acting on O 6 MeG/T lesions, provoke a repetitive faulty MMR cycle (Karran and Bignami, 1994) , ending up with the formation of secondary lesions and, during DNA replication, DSBs that act as a final trigger of O 6 MeGinduced apoptosis (Ochs and Kaina, 2000) . The last model implicates DNA replication and DSB formation to be essential elements of O 6 MeG-triggered apoptosis. To prove this model, we compared apoptosis induced by the O 6 MeG-generating agent MNNG and the similar acting tumor-therapeutic drug temozolomide in human resting peripheral lymphocytes and lymphocytes that were stimulated to divide. We show that with moderate doses of MNNG (o15 mM), which are cytotoxic and genotoxic also in other Mex À cell types (e.g., Chinese hamster fibroblasts), but still allow cells to recover and divide (Kaina, 1985; Kaina et al., 1991) , apoptosis was strongly enhanced when lymphocytes were proliferating and MGMT was inactivated by O 6 BG. Under the same treatment conditions, nonproliferating lymphocytes were completely resistant to the induction of apoptosis. This clearly shows that nonrepaired O 6 MeG lesions trigger apoptosis in a replication-dependent manner. However, with high doses of MNNG (X15 mM), apoptosis was also induced in nonproliferating cells, albeit at a lower level not exceeding 25% compared to the nontreated control. This occurred both in the presence and absence of O 6 BG, indicating that with high alkylation levels, N-alkylations come into play provoking apoptosis in a replication-independent manner. This is in line with conclusions drawn on the basis of dose-response curves of genotoxicity in Mex À versus Mex þ isogenic cell lines that suggested N-alkylations to be mainly responsible for genotoxic effects of S N 1 agents if they were applied at high-dose levels and for S N 2 agents that induce only low amounts of O-alkylations (Kaina et al., 1993) .
The requirement of DNA replication for the conversion of O 6 MeG into an apoptotic lesion was also found for Mex À CHO fibroblasts in which apoptosis was drastically reduced if they were maintained under nondividing conditions (unpublished data MeG/T lesions are formed in the treatment cell cycle (pre-and postreplicatively). On the other hand, genotoxicity and apoptosis induced by O 6 MeG is a late response occurring in the subsequent cell cycles (Kaina et al., 1997; Ochs and Kaina, 2000) . This, however, is incompatible with the hypothesis of MutSa being a sensor of O 6 MeG lesions triggering apoptosis by direct signaling. The data are more compatible with a model suggesting that O 6 MeG/T lesions are processed erroneously by MutSa-mediated MMR, which in turn creates secondary DNA lesions. These lesions interfere with the subsequent DNA replication, giving rise to either sister chromatid exchanges (SCEs), which are thought to result from a recombination process circumventing replication blocking lesions (Kaina et al., 1997) or DSBs. If not repaired, they will finally be expressed as aberrations (Galloway et al., 1995; Kaina et al., 1997) or act as a distal trigger of apoptosis as shown in experiments with electroporated restriction enzymes (Lips and Kaina, 2001 ).
Similar to Mex À Chinese hamster cells (Ochs and Kaina, 2000) , DSBs were formed upon low dose (10 mM) of MNNG treatment in human peripheral lymphocytes that were stimulated to divide and in which MGMT was depleted by O 6 BG. In nondividing lymphocytes, this treatment did not result in DSBs. The wave of DSBs was observed 24 h after treatment, which preceded apoptosis. Interestingly, DSBs were also observed in resting lymphocytes when they were treated with a high dose of MNNG (25 mM), which induced apoptosis replication independently. These replication-independent DSBs originated very likely from overlapping base excision repair (BER) patches, which may occur at high DNA alkylation levels (Coquerelle et al., 1995) .
Ionizing radiation is a well-known inducer of cell death, which was shown to be related to the level of nonrepaired DSBs (Dikomey et al., 1998) . To see whether proliferation exerts an influence on radiationinduced apoptosis, we compared g-ray-treated proliferating and nonproliferating lymphocytes with respect to their apoptotic response. Interestingly, proliferating and nonproliferating lymphocytes showed a very similar level of apoptosis. This shows that both resting and stimulated lymphocytes basically have the ability to undergo apoptosis. It also demonstrates that apoptosis in lymphocytes following ionizing radiation is a replication-independent process. This again supports the hypothesis that DSBs act as an ultimate trigger of MNNG-induced apoptosis.
Simultaneous with DSBs, we observed an increase in the level of p53 in proliferating lymphocytes. p53 induction was not observed in nonreplicating lymphocytes treated with low MNNG doses. This suggests that DSBs resulting from erroneous processing of O 6 MeG lesions act as a trigger of p53 stabilization. It is not yet clear whether DNA single-strand breaks (SSBs) provoke p53 stabilization. SSBs were formed with low doses of MNNG because of base hydrolysis and cleavage of apurinic sites during BER early after MNNG treatment, which occurred in proliferating and resting cells (unpublished data). Since in resting lymphocytes, p53 was not detectably elevated at dose levels below 15 mM, its induction appears likely to be dependent on the formation of DSBs.
In Chinese hamster fibroblasts, a hallmark of O 6 MeG-triggered apoptosis is Bcl-2 decline (Ochs and Kaina, 2000) , which is provoked by proteosomal degradation and occurs independent of p53 (Dunkern and Kaina, 2002) . The Bcl-2 decline was also involved in apoptosis in DNA repair-deficient rodent fibroblasts treated with UV light (Dunkern et al., 2001b) , cisplatin (Dunkern et al., 2001a) , glufosfamide (Becker et al., 2002) and methyl methanesulfonate (Ochs et al., 2002) . As shown here, contrary to fibroblasts, the Bcl-2 level remained constant upon MNNG treatment in lymphocytes, irrespective of the proliferation state. There was also no change in the level of Bax, indicating that in lymphocytes O 6 MeG does not trigger the mitochondrial damage pathway. However, we observed a significant increase in the level of Fas receptor; the Fas ligand remained constant. Fas upregulation occurred 24 h after MNNG treatment with doses o15 mM in proliferating cells pretreated with O 6 BG, but not resting cells, indicating O 6 MeG lesions processed by MMR and replication to be responsible for Fas upregulation. Fas induction coincided with p53 accumulation in MNNGtreated proliferating lymphocytes. The promoter of fas (CD95, apo-1) harbors a p53 binding site and was shown to be subject to regulation by p53 (Muller et al., 1998) . Based on this, we infer that DSBs resulting from erroneous processing of O 6 MeG lesions and replication provoke an increase in the p53 level, which stimulates Fas expression that signals apoptosis. To test the significance of Fas in apoptosis signaling, we inactivated the Fas receptor using an anti-Fas neutralizing antibody. This led to a significant reduction in O 6 MeGinduced apoptosis, once again confirming the role of Fas. Contrary to lymphocytes, in CHO fibroblasts O 6 MeG does not activate Fas (Ochs and Kaina, 2000 ), which appears not to be inducible also by other genotoxic agents such as UV light (Dunkern et al., 2001a) . Therefore, O 6 MeG-induced stimulation of Fas appears to be cell-type specific. Why O 6 MeG lesions trigger the p53-dependent Fas pathway in peripheral lymphocytes and lymphoblastoid cell lines (Dunkern et al., 2003) , whereas in fibroblasts the same primary signal activates the mitochondrial pathway, is an open question that still remains to be solved.
The Fas system can be activated both by upregulation of the Fas receptor and the corresponding ligand. Fas-L is controlled by Fos/Jun/AP-1 (Kasibhatla et al., 1998) , which is immediate-early inducible by genotoxic stress (Holbrook and Fornace, 1991) . Fos/Jun as well as the binding activity of AP-1 has been shown to be induced by MNNG in fibroblasts with quite high doses (>20 mM) with a response indifferent from the MGMT status . Therefore, in fibroblasts treated with MNNG, immediate-early AP-1 induction is likely not to be decisively involved in O 6 MeG-triggered apoptosis. Theoretically, AP-1 could become induced in lymphocytes upon MNNG treatment, thus triggering Fas-L expression. However, with doses effectively inducing apoptosis (o15 mM), we were unable to detect any rise in c-Jun level both immediately or late after MNNG exposure (data not shown). It thus appears that DSBs triggering p53 stabilization 24 h after methylation do not provoke c-Jun induction. Data also suggest that c-Jun induction observed in other experimental systems provoking an increase in Fas-L expression, for example, upon cisplatin treatment (Mansouri et al., 2003) , is mediated by signals other than DSBs. This is in accordance with the finding that ionizing radiation is a weak inducer of Fos/Jun/AP-1 (Raju et al., 2000) and Fas-L (Jones et al., 2001) .
In summary, we have shown that a specific welldefined type of DNA damage, O 6 MeG, triggers in human lymphocytes apoptosis by activating the Fasdependent death receptor pathway. This requires DNA replication and occurs by converting O 6 MeG lesions into DSBs that act as an ultimate trigger for the upregulation of p53, which stimulates fas expression. With very high doses of MNNG (X15 mM) inducing apoptosis also in resting cells, DSBs can be formed in a replication-independent manner, provoking an early rise in p53 level, Fas and cell death. This occurs independent of O 6 MeG and is likely to be due to non-or mis-repaired N-alkylation lesions that have previously been shown to exert apoptotic activity (Ochs et al., 2002) . The relevance of these findings for tumor therapy are obvious. Thus, in the therapy of tumors with O 6 -methylating agents (dacarbazine, procarbazine, streptozotozine, mitozolomide, temozolomide), drug plasma levels should not exceed the level that would be able to kill nonproliferating cells in order to reduce systemic side effects. For temozolomide, blood plasma levels have been reported during the therapy, which were below 50 mM (Hammond et al., 1999) . With this dose, nonproliferating lymphocytes will not be killed, whereas the rapidly proliferating tumor cell population will be targeted. An important replicating population, which should be protected, is blood stem cells (CD34 þ ). They express very low levels of MGMT (Gerson et al., 1996 and own unpublished data) and will therefore inevitably be targeted by methylating drugs. Protection of this population during methylating agent therapy is envisaged by MGMT gene transfer and corresponding strategies are being developed (Moritz et al., 1995) . The requirement of cell proliferation for the conversion of preapoptotic O 6 MeG into critical ultimate apoptotic lesions may explain not only the specificity of methylating anticancer drugs and their systemic side effects but also implicates that slow-growing tumors will be less susceptible to O 6 -alkylating agents than fast-growing tumors. In combination therapy, regimens should therefore be avoided that transiently inhibit the proliferation of tumor cells, which may attenuate the killing effect of O 6 -methylating drugs. Finally, in prescreening approaches, attention should be paid to the MGMT and MMR level as well as the proliferation index and the type of apoptotic pathway evoked, since these factors appear to be most important determinants for the effectiveness of methylating anticancer drugs.
Materials and methods
Lymphocyte preparation and drug treatment
Lymphocytes were isolated from buffy-coat blood by density centrifugation. First, the blood was diluted by the addition of an equal volume of phosphate-buffered saline (PBS). A volume of 25 ml diluted blood was then carefully layered over 15 ml Lymphoprep TM (PROGEN Biotechnik GmbH, Heidelberg, Germany) in a sterile 50 ml centrifuge tube. After centrifugation (800 g in swing-out rotor), the lymphocytes were washed 3 Â with PBS before being suspended in RPMI-1640 (3 mg/ml L-glutamine, 110 mg/ml sodium pyruvate, 0.5 g/l sodium bicarbonate, 3.5 Â 10 À4 % 2-mercaptoethanol, 15% fetal bovine serum) medium (2 Â 10 6 cells per ml). Lymphocytes were cultivated overnight at 371C in a humidified atmosphere at 95% air and 5% CO 2 before stimulation. For growth stimulation, lymphocytes were incubated for 24 h in 24-well tissue culture plates containing plastic-bound anti-CD3 (BD PharMingen, Heidelberg, Germany) plus anti-CD28 (BD PharMingen, Heidelberg, Germany) antibodies. This stimulation yielded highly reproducible results and was much more effective than phytohemaglutinin, which was ineffective in stimulating a significant number of cells (background experiments). All experiments were performed in parallel on CD3/ CD28 stimulated and nonstimulated cells. A 10 mM MNNG stock solution was prepared by dissolving MNNG in dimethyl sulfoxide (DMSO) and then diluting it with sterile dH 2 O. Temozolomide stocks (35 mM) were prepared by dissolving the drug in ethanol and diluting it with dH 2 O. The MNNG and temozolomide stocks were filtered, aliquated and stored at À801C. To determine the contribution of MGMT on apoptosis, cells were pretreated with 10 mM O 6 BG 1 h before MNNG treatment. This concentration of O 6 BG was highly effective in depleting cells completely with respect to MGMT activity, which in undepleted cells was in the range of 400-600 fmol/mg protein (Janssen et al., 2001) . Cells were stimulated with anti-CD3 and anti-CD28 for 24 h before mutagen treatment.
Irradiation
Irradiation of lymphocytes was performed in growth medium using a 137 Cs source at a dose rate of 4 Gy/min. For apoptosis determination after 5 Gy irradiation, exponentially growing cell suspensions were irradiated at room temperature.
Quantification of apoptosis
Sub-G1 The apoptotic response after genotoxic drug treatment was measured using the flow cytometric method of sub-G1 determination, which yielded consistent and reproducible results with diploid cells (our background experiments). Ethanol (70%) fixed cells were stained with propidium iodide (16.5 mg/ml) in PBS after RNase (0.03 mg/ml) digestion. Samples were analysed on a FACS Calibur (Becton Dickinson). For each sample 10 000 cells were analysed. The number of apoptotic cells was calculated using a computer program (Cellquest software).
Annexin V The frequency of apoptosis in untreated cell populations, MNNG-and O 6 BG-treated cells and cells where the Fas death receptor was neutralized using an anti-Fas neutralizing antibody (MBL International, Watertown, MA, USA) was determined using Annexin V and flow cytometry (Vermes et al., 1995) . In this assay, unfixed cells were doublestained with Annexin V and propidium iodide, which allows differentiation between apoptotic and necrotic cells. Lymphocytes stimulated for growth were treated with 10 mM O 6 BG 1 h before MNNG (5 mM) treatment. Apoptosis was inhibited by adding anti-Fas neutralizing antibody (1 mg/ml) every 24 h and samples were stopped at 96 h. Cells were harvested, washed with cold PBS, subjected to Annexin V and propidium iodide staining (according to the manufacturer's protocol; Annexin V-FITC; PharMingen) and to flow cytometry measurement. The evaluation of cell populations was performed using a computer-based program (Cellquest, Becton Dickinson).
Determination of DSBs
Comet assay DSBs were determined and quantified by the highly sensitive neutral single-cell gel electrophoresis assay (comet assay). The procedure (Olive et al., 1991) was modified as follows. Lymphocytes were seeded in a 24-well plate (1 Â 10 5 for stimulated and 3 Â 10 5 for nonstimulated) and treated 24 h later with 10 mM MNNG. At various times after treatment, cells were harvested, washed with cold PBS and kept on ice until assayed. Cells were embedded in 0.5% low melting point agarose, and microscope slides were immersed in ice-cold lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% sodium laurylsarcosine (pH 7), 1% Triton X-100, and 10% DMSO were added freshly) and maintained at 41C for 1 h. After lysis, electrophoresis (25 V) was carried out at 41C for 15 min in 90 mM Tris, 90 mM boric acid and 2 mM EDTA. The fixed and ethidium bromide-stained slides were analysed using a fluorescence microscope. The analysis of DNA migration was performed by an image analysis system (Kinetic Imaging LTD.; komet 4.0.2; Optilas), determining the median tail moment (percentage of DNA in the tail Â tail length) of 50 cells/sample.
Expression of H2AX-P Phosphorylation of histone H2AX has been shown to be a highly sensitive indicator of the presence of DSBs. Therefore, we made use of this for determining the level of H2AX phosphorylation in Western blot experiments as described below. A specific antibody that recognizes phosphorylated H2AX (Upstate Biotechnology, Lake Placid, NY, USA) was used in Western blot analysis as described below.
Preparation of cell extracts
The suspension was washed two times with cold PBS and then lysed in cold RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA) containing the proteinase inhibition cocktail Complete TM Mini (Roche). The lysate was then centrifuged at 14 000 g in a precooled centrifuge for 15 min. The supernatant was transferred to a fresh centrifuge tube and the pellet was discarded. For Fas, the detergents were excluded from the buffer and the membrane fraction was dissolved in buffer containing 1% Triton X-100. Protein concentration determination was conducted on a 1 : 10 dilution using the Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH, Mu¨nchen, Germany) to prevent interference of the detergents on results.
Western blot analysis
Protein (30 mg) of cell extracts was separated on a 12% SDSpolyacrylamide gel. Thereafter, proteins were blotted onto a nitrocellulose transfer membrane (Protran; Schleicher and Schuell, Dassel, Germany) for 3 h. The membranes were blocked for 2 h at room temperature in 5% (wt/vol) milk powder in PBS containing 0.1% Tween 20, incubated overnight at 41C with the primary antibody (1 : 500-1000 dilution), washed three times with 0.1% Tween 20 in PBS and incubated for 1 h with a horseradish peroxidase-coupled secondary antibody 1 : 3000 (Amersham Biosciences AB, Uppsala, Sweden). The antibodies used were anti-P53 (BD PharMingen, Heidelberg, Germany), anti-Fas, anti-Bcl-2 and anti-Bax (Santa Cruz Biotechnology, Inc., CA, USA). After final washing with 0.1% Tween 20 in PBS (three times for 10 min each), blots were developed using a chemiluminescence detection system (Amersham Biosciences AB, Canada).
